Akeso: Carcinoma, Hepatocellular trials
The registry lists 10 Carcinoma, Hepatocellular studies with Akeso as lead sponsor. 5 are open to participants now and 0 have results posted.
Phase 1 2Phase 2 8Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingNCT07052253Phase 2
- A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingNCT06530251Phase 1/2
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Phase 3
- A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative ResectionRecruitingNCT05489289Phase 3
- A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT05432492Phase 2
- A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Phase 2
- A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04728321Phase 2
- A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaCompletedNCT04444167Phase 1/2
- A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)CompletedNCT04172571Phase 2